//img.uscri.be/pth/e1a65299fef8994e52f0794505a25d29fbd36314
Cet ouvrage fait partie de la bibliothèque YouScribe
Obtenez un accès à la bibliothèque pour le lire en ligne
En savoir plus

Drawbacks in Current Rheumatoid Arthritis Therapies Point to a Large Untapped Market in the U.S., Finds Frost & Sullivan

2 pages
Drawbacks in Current Rheumatoid Arthritis Therapies Point to a Large Untapped Market in the U.S., Finds Frost & Sullivan PR Newswire MOUNTAIN VIEW, California, Oct. 18, 2012 -- Emerging remedies must demonstrate a high degree of safety and efficacy to gain acceptance MOUNTAIN VIEW, California, Oct. 18, 2012 /PRNewswire/ -- The availability of tumor necrosis factor (TNF) inhibitors has greatly improved the pharmacological management of rheumatoid arthritis (RA). Both patients and physicians are familiar with TNF inhibitors due to their long history; however, their many limitations such as high cost, potential side effects, and injection requirement have created a need for alternative therapies. This need, along with a potentially large patient pool, is encouraging pharmaceutical and biotechnology companies with disease expertise to break into this sizeable market. New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com) United States Market for Rheumatoid Arthritis Pharmacotherapeutics research finds that the market earned revenues of more than $7.74 billion in 2011 and estimates this to reach $11.79 billion in 2017. If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country. RA is an incurable chronic condition that affects 2.
Voir plus Voir moins
Drawbacks in Current Rheumatoid Arthritis Therapies Point to a Large Untapped Market in the U.S., Finds Frost & Sullivan
PR Newswire MOUNTAIN VIEW, California, Oct. 18, 2012
-- Emerging remedies must demonstrate a high degree of safety and efficacy to gain acceptance
MOUNTAIN VIEW, California,Oct. 18, 2012/PRNewswire/ -- The availability of tumor necrosis factor (TNF) inhibitors has greatly improved the pharmacological management of rheumatoid arthritis (RA). Both patients and physicians are familiar with TNF inhibitors due to their long history; however, their many limitations such as high cost, potential side effects, and injection requirement have created a need for alternative therapies. This need, along with a potentially large patient pool, is encouraging pharmaceutical and biotechnology companies with disease expertise to break into this sizeable market.
New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com)United States Market for Rheumatoid Arthritis Pharmacotherapeuticsore thanresearch finds that the market earned revenues of m $7.74 billionin 2011 and estimates this to reach$11.79 billionin 2017.
If you are interested in more information on this research, please send an email toBritni Myers, Corporate Communications, atbritni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
RA is an incurable chronic condition that affects 2.3 million adults inthe United States. Although the overall disease prevalence is not expected to change significantly, the eligible patient community is likely to grow owing to an aging population, increasing longevity, and changing clinical trends, such as new criteria for diagnosis as well as quicker identification and treatment.
"While TNF inhibitors have laid the groundwork for the next generation of effective, disease-modifying anti-rheumatic treatment and biologics, the need of the hour is patient-friendly options with improved profiles, such as oral administration or enhanced tolerability," said Frost & Sullivan Senior Industry Analyst Deborah Toscano. "These novel drugs could offer better long-term clinical outcomes."
However, slow uptake of these new drugs by a conservative regulatory and medical community is likely until they are proven in the market. To gain end-user confidence, companies must make products with a high degree of safety, with significant clinical or economic benefits over TNF inhibitors.
"Active marketing of these innovative and effective therapies will renew interest in RA drugs and increase diagnosis, fueling greater adoption and market expansion," noted Toscano.
United States Market for Rheumatoid Arthritis Pharm acotherapeuticsis part of theLife SciencesGrowth Partnership Services program, which also includes research in the following markets: United States Market for Ankylosing Spondylitis Pharmacotherapy, United States Market for Psoriatic Arthritis Pharmacotherapy, U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments, and United States Rheumatic Diseases Therapeutics Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, w orks in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Propositionprovides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation. The Partnership Infrastructureis entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of m ore than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?